<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01739465</url>
  </required_header>
  <id_info>
    <org_study_id>RFA2012</org_study_id>
    <nct_id>NCT01739465</nct_id>
  </id_info>
  <brief_title>Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma</brief_title>
  <official_title>A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Medical University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare endoscopic radiofrequency ablation with photodynamic
      therapy for inoperable cholangiocarcinoma
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stent patency</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Self expanding metallic stent （SEMS ）placement only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endoscopic radiofrequency ablation plus SEMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. The radiofrequency ablation (RFA) catheter (EMcision, London, United Kingdom) would be placed under fluoroscopic guidance across the biliary stricture. Radiofrequency energy will be delivered to the malignant site. After that,A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Photodynamic therapy plus SEMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Photofrin is injected 3 days prior to laser activation of the agent.Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) will be carried out to determine the length and positon of the biliary malignant. Delivery Fiber used along with the laser system to activate the photosensitizing agent and induce tumor tissue necrosis. A self expanding metallic stent (SEMS) will be placed the site of biliary narrowing</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Self expanding metallic stent (SEMS)</intervention_name>
    <description>Self expanding metallic stent</description>
    <arm_group_label>Self expanding metallic stent （SEMS ）placement only</arm_group_label>
    <arm_group_label>Endoscopic radiofrequency ablation plus SEMS</arm_group_label>
    <arm_group_label>Photodynamic therapy plus SEMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic radiofrequency ablation (ERFA)</intervention_name>
    <description>Endoscopic radiofrequency ablation</description>
    <arm_group_label>Endoscopic radiofrequency ablation plus SEMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photodynamic therapy (PDT)</intervention_name>
    <description>Photodynamic therapy</description>
    <arm_group_label>Photodynamic therapy plus SEMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Pathologically or radiologically confirmed biliary malignant

          -  Inoperability by staging

        Exclusion Criteria:

          -  Cholangiocarcinoma with widespread metastasis

          -  Coagulopathy (INR &gt; 2.0 or prothrombin time &gt; 100 sec or platelet count &lt; 50,000)

          -  Prior SEMS placement

          -  Pregnancy

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3 )

          -  Life expectancy &lt; 3months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huihong Liang, MD</last_name>
    <phone>+86-20-34153043</phone>
    <email>beanth@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Hospital of Guangzhou Medical College</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huihong Liang, MD</last_name>
      <phone>+86-188-2648-8232</phone>
      <email>beanth@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The second hospital of Guangzhou Medical college</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huihong Liang, Doctorial</last_name>
      <phone>+86-188-2648-8232</phone>
      <email>beanth@163.com</email>
    </contact>
    <investigator>
      <last_name>Huihong Liang, Doctoral</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2012</study_first_submitted>
  <study_first_submitted_qc>November 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2012</study_first_posted>
  <last_update_submitted>February 25, 2013</last_update_submitted>
  <last_update_submitted_qc>February 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Huihong Liang</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Pathologic</keyword>
  <keyword>Digestive System</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Bile Duct Diseases</keyword>
  <keyword>Biliary Tract Diseases</keyword>
  <keyword>Pathological Conditions</keyword>
  <keyword>Constriction</keyword>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

